13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case

Background. Vaccination coverage in patients with rheumatic diseases remains extremely low. Moreover, infections are the leading cause of death in such patients. Respiratory infections mortality is 2–5 times higher in adults with rheumatoid arthritis than in overall population. The most frequent inf...

Полное описание

Библиографические подробности

Главные авторы:	Ekaterina I. Alekseeva, Dar’ya D. Van’kova, Tatyana M. Dvoryakovskaya, Kseniya B. Isaeva, Rina V. Denisova, Anna V. Mamutova, Aleksandra M. Chomahidze, Nikolay A. Mayanskiy, Natalya E. Tkachenko, Maria V. Kurdup, Tatyana V. Radygina, Irina V. Zubkova
Формат:	Artigo
Язык:	Inglês
Опубликовано:	"Paediatrician" Publishers LLC 2019-09-01
Серии:	Вопросы современной педиатрии
Предметы:	children pneumococcal disease vaccination 13-valent pneumococcal conjugate vaccine haemophilus influenzae-tetanus toxoid conjugate vaccine tocilizumab systemic juvenile idiopathic arthritis
Online-ссылка:	https://vsp.spr-journal.ru/jour/article/view/2137
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!